Javascript must be enabled to continue!
RPTPγ is a redox-regulated suppressor of promigratory EGFR signaling
View through CrossRef
AbstractSpatially-organized interaction dynamics between proto-oncogenic epidermal growth factor receptor (EGFR) and protein tyrosine phosphatases (PTPs) determine EGFR’s phosphorylation response to growth factors and thereby cellular behavior within developing tissues. We show here, that and how the coupling between EGFR and RPTPγ activity leads to migratory signaling responses to very low, physiological growth factor stimuli while suppressing aberrant, spontaneous signaling. Single cell imaging of EGFR phosphorylation and PTP oxidation revealed that RPTPγ fully suppresses spontaneous EGFR phosphorylation, while EGF-induced NADPH-oxidase activity enables promigratory signaling responses at the plasma membrane by H2O2-mediated oxidative inhibition of RPTPγ’s phosphatase activity. The EGF-dependent toggle switch dynamics between interacting EGFR monomers and RPTPγ thereby enables autocatalytically amplified phosphorylation responses to very low, physiological, EGF levels even at sparse receptor expression. This signaling mechanism is distinct from the proliferative signaling stemming from liganded endosomal EGFR complexes at high growth factor concentrations. Accordingly, RPTPγ knock-out results in spontaneous promigratory EGFR signaling but loss of proliferative signaling. We thereby provide evidence of RPTPγ’s suppressor function of oncogenic, promigratory EGFR-signaling from the plasma membrane.
Cold Spring Harbor Laboratory
Title: RPTPγ is a redox-regulated suppressor of promigratory EGFR signaling
Description:
AbstractSpatially-organized interaction dynamics between proto-oncogenic epidermal growth factor receptor (EGFR) and protein tyrosine phosphatases (PTPs) determine EGFR’s phosphorylation response to growth factors and thereby cellular behavior within developing tissues.
We show here, that and how the coupling between EGFR and RPTPγ activity leads to migratory signaling responses to very low, physiological growth factor stimuli while suppressing aberrant, spontaneous signaling.
Single cell imaging of EGFR phosphorylation and PTP oxidation revealed that RPTPγ fully suppresses spontaneous EGFR phosphorylation, while EGF-induced NADPH-oxidase activity enables promigratory signaling responses at the plasma membrane by H2O2-mediated oxidative inhibition of RPTPγ’s phosphatase activity.
The EGF-dependent toggle switch dynamics between interacting EGFR monomers and RPTPγ thereby enables autocatalytically amplified phosphorylation responses to very low, physiological, EGF levels even at sparse receptor expression.
This signaling mechanism is distinct from the proliferative signaling stemming from liganded endosomal EGFR complexes at high growth factor concentrations.
Accordingly, RPTPγ knock-out results in spontaneous promigratory EGFR signaling but loss of proliferative signaling.
We thereby provide evidence of RPTPγ’s suppressor function of oncogenic, promigratory EGFR-signaling from the plasma membrane.
Related Results
Effect of knocking out receptor protein tyrosine phosphatase γ (RPTPγ) in the HCO
3
‐induced inhibition of HCO
3
reabsorption by mouse renal proximal tubules
Effect of knocking out receptor protein tyrosine phosphatase γ (RPTPγ) in the HCO
3
‐induced inhibition of HCO
3
reabsorption by mouse renal proximal tubules
The accompanying abstract shows that knocking out RPTPγ renders isolated perfused proximal tubules (PTs) incapable of responding to changes in basolateral (BL) [CO
...
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract
EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four EGFR...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling
Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling
Abstract
Complete responses to ALK tyrosine kinase inhibitors (TKIs) are rare and resistance eventually develops in ALK fusion-positive non-small cell lung cancer pa...
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract
Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to first generation rev...
EGFR Signaling in Osteoblasts Regulates Circadian Rhythm of HSPC in Circulation
EGFR Signaling in Osteoblasts Regulates Circadian Rhythm of HSPC in Circulation
Abstract
EGFR signaling regulates growth, differentiation, proliferation and migration in multiple organ systems. We previously demonstrated that inhibition of EGFR ...
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers which the leading cause of cancer-related death worldwide. Recently, epide...
Data from EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma
Data from EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma
<div>Abstract<p>Hyperactivated EGFR signaling is a driver of various human cancers, including glioblastoma (GBM). Effective EGFR-targeted therapies rely on knowledge of...

